These three compounds get filed under peptides for muscle growth. That label is the source of most of the confusion in this space.
These three compounds do not do the same thing. They do not produce the same results. And expecting any of them to perform like exogenous growth hormone is the fastest way to conclude they failed when they actually did exactly what they were designed to do. Neither tesamorelin nor CJC-1295 gives you exogenous growth hormone. Both stimulate your own pituitary to release growth hormone within your natural limits, which means no supraphysiological elevation and no hormonal replacement. Your age, recovery quality, and nutrition still cap the response. This single fact explains most of the confusion researchers have when these compounds appear to underperform.
What this guide covers
Who this is for
Researchers using tesamorelin or CJC-1295 who are not seeing the muscle results they expected.
Anyone considering IGF-1 LR3 who has not yet established a GH secretagogue foundation.
Researchers on a GLP-1 protocol who are experiencing lean mass loss and need to understand what actually protects muscle during a caloric deficit.
Tesamorelin: muscle protector not muscle builder
Most researchers assume tesamorelin builds muscle. Research does not support that framing. What it does is reduce the conditions that cause muscle loss. It improves growth hormone pulse quality, sleep architecture, recovery consistency, and fat distribution. What researchers typically notice is less muscle loss while cutting, better recovery between sessions, muscles that look fuller over time, and more consistent training across weeks. What they will not get is faster hypertrophy or meaningful strength gains on their own.
The fact that it protects muscle so well during caloric restriction is exactly why it pairs well with retatrutide once adaptation starts to occur. If you expect more than preservation from tesamorelin you will assume it failed when it did everything it was designed to do. For the comparison between tesamorelin and CJC-1295 as GHRH options, see the CJC-1295 vs tesamorelin breakdown.
How these compounds compare
The table below shows what each compound actually does versus the most common misread researchers make.
| Compound | What it does | Most common misread |
|---|---|---|
| Tesamorelin | Improves GH pulse quality, sleep, recovery, and fat distribution. Protects muscle during deficit. | Assumed to build muscle. It preserves it. |
| CJC-1295 | Improves GH pulse signaling, connective tissue recovery, and training tolerance. | Assumed to be directly anabolic. It is not. The results are indirect. |
| IGF-1 LR3 | Delivers IGF-1 signaling directly at the muscle level. Supports nutrient uptake and satellite cell activity. | Run too early before the recovery foundation is in place. It amplifies what exists. It does not create from nothing. |
The Protocol Intelligence Tool maps every compound in your stack to its receptor targets and flags where two compounds are driving the same binding site. For this combination it identifies the shared pathways and shows exactly where the signals converge. That picture is what the receptor map requires before any stacking decision can be evaluated accurately.
Run the Protocol Intelligence ToolCJC-1295 no DAC: indirect muscle support through training capacity
CJC-1295 without DAC does not build muscle directly. For researchers using it correctly it can feel like it does, and that is because of what it actually produces. It improves GH pulse signaling, connective tissue recovery, and training tolerance. Those three things lead to higher training volume, better weekly progression, and fewer missed sessions. The result over time is that training accumulates rather than breaking down between sessions.
Researchers who understand it is not anabolic get results. Those who expect anabolic results conclude it failed. For beginners and intermediate researchers, CJC-1295 paired with ipamorelin is the foundational GH secretagogue stack and the rational starting point before any more advanced compound is considered. See the full breakdown on the CJC-1295 and ipamorelin foundation page.
The free protocol check maps your current compounds to the bottleneck they were built to solve. If the bottleneck has already been addressed, it flags it. Before adding a second compound, knowing which variable is actually limiting the result is the more useful starting point than assuming more is better.
Run the Free Protocol CheckIGF-1 LR3: the only compound with direct muscle influence
IGF-1 LR3 is the most misunderstood compound on this list and the only one with direct influence on muscle tissue. Rather than relying on the normal pituitary-to-liver signaling chain, it delivers IGF-1 activity directly at the muscle level, supporting nutrient uptake, satellite cell activity (the cells that contribute to muscle repair and growth), and localized hypertrophy. This is why size and strength responses are more noticeable when it works.
The consistent mistake is running it before the foundation is in place. Recovery, sleep, and protein intake have to be stable before IGF-1 LR3 has anything meaningful to amplify. It can only work with what the system can already support. Research frameworks treat this as an advanced compound, added after a CJC-1295 and ipamorelin stack has been running for at least four weeks and lean mass loss is still occurring. Research frameworks typically use four to six week cycles with defined off periods to account for potential receptor desensitization, though individual response varies. For researchers experiencing lean mass loss on a GLP-1 protocol, the foundation section of the peptides for muscle growth guide covers where to start before considering IGF-1 LR3.
IGF-1 LR3 added before the CJC-ipamorelin foundation is established. The amplification signal has nothing to work with and results appear absent.
CJC-1295 and ipamorelin running for four or more weeks. Recovery, sleep, and protein stable. IGF-1 LR3 now has a system it can amplify.
Researcher expects muscle gain. Tesamorelin protects muscle and improves recovery but does not drive hypertrophy. The compound performed correctly.
IGF-1 LR3 run past six weeks without a break. Research frameworks use defined cycles with rest periods to account for potential receptor desensitization.
The right compound at the right stage
Most of the confusion in this space comes from grouping these three compounds into one category and expecting the same result from each. Tesamorelin protects. CJC-1295 builds training capacity. IGF-1 LR3 amplifies what the system can already support. None of them perform like exogenous growth hormone and none of them produce results when added before the foundation that makes them work is in place.
Sequencing matters more than compound selection. Getting the stage right consistently outperforms adding the more advanced compound too early.
Frequently Asked Questions
Does tesamorelin build muscle?
Research does not support tesamorelin as a muscle builder. What it does is reduce the conditions that cause muscle loss by improving growth hormone pulse quality, sleep architecture, recovery consistency, and fat distribution. Researchers typically notice less muscle loss while cutting and better recovery between sessions, not faster hypertrophy.
What is the difference between tesamorelin and CJC-1295?
Both are GHRH analogs that stimulate your own pituitary to release growth hormone within natural limits. Tesamorelin is more studied for visceral fat reduction and muscle preservation during deficit. CJC-1295 without DAC improves GH pulse signaling, connective tissue recovery, and training tolerance, making it the more common foundational stack option when paired with ipamorelin.
When should IGF-1 LR3 be added to a protocol?
Research frameworks treat IGF-1 LR3 as an advanced compound. It is typically added after a CJC-1295 and ipamorelin stack has been running for at least four weeks and recovery, sleep, and protein intake are stable. Running it before the foundation is in place consistently underdelivers because IGF-1 LR3 amplifies what the system can already support rather than creating results from nothing.
How long should an IGF-1 LR3 cycle run?
Research frameworks typically use four to six week cycles with defined off periods to account for potential receptor desensitization, though individual response varies. Running past six weeks without a break tends to reduce the response over time.
This post covers the core logic. The membership goes further — the stack visualizer maps every compound in your protocol to its receptor targets and flags when two compounds are covering the same pathway, so you can see the overlap before it becomes a problem.
Members get the full stack visualizer, the deep dive PDF for this video, and a library of over 50 deep dive PDFs built from the YouTube video catalog, with one to two new deep dives added every week. The library grows every time a new video publishes.
For educational and research purposes only | Not medical advice | Not for human use guidance | Project Theo